By Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F and Filippi AR. (2021). Front. Oncol. 11:744956. doi: 10.3389/fonc.2021.744956
In the original article there was an error. The survival numbers were incorrect.
A correction has been made to Abstract:
“1-year PFS and OS were 83.5% (95%CI: 77.6-89.7) and 97.2% (95%CI: 94.6-99.9), respectively.”
“1-year PFS and OS were 65.5% (95%CI: 57.6-74.4) and 87.9% (95%CI: 82.26.6-93.9), respectively”
In the original article, there was an error. The survival numbers were incorrect.
A correction has been made to Results, Survival:
“PFS at 12, 18, and 24 months was 83.5% (95%CI: 77.6–89.7), 65.5 (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 12, 18, and 24 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1).”
“PFS at 6, 12, and 18 months was 83.5% (95%CI: 77.6–89.7), 65.5% (95%CI: 57.6–74.4), and 53.1% (95%CI: 43.8–64.3), respectively. (Figure 1). OS at 6, 12, and 18 months was 97.2% (95%CI: 94.6– 99.9), 87.9% (95%CI: 82.26–93.9), and 79.3% (95%CI: 71.1–88.4), respectively (Figure 1)”
In the original article, there was an error. The survival numbers were incorrect.
A correction has been made to Discussion:
“12-month PFS was 83.5%, and OS 97.2%”
“12-month PFS was 65.5%, and OS 87.9%”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: chemoradiotherapy, immunotherapy, stage III, unresectable, NSCLC
Citation: Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D’Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F and Filippi AR (2021) Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front. Oncol. 11:802949. doi: 10.3389/fonc.2021.802949
Received: 27 October 2021; Accepted: 04 November 2021;
Published: 16 November 2021.
Edited and reviewed by:
Aditya Juloori, University of Chicago Medical Center, United StatesCopyright © 2021 Bruni, Scotti, Borghetti, Vagge, Cozzi, D’Angelo, Giaj Levra, Fozza, Taraborrelli, Piperno, Vanoni, Sepulcri, Trovò, Nardone, Lattanzi, Bou Selman, Bertolini, Franceschini, Agustoni, Jereczek-Fossa, Magrini, Livi, Lohr and Filippi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alessio Bruni, bruni.alessio@aou.mo.it
Alessio Bruni
1*